Illumina, Inc. (NASDAQ:ILMN) has been assigned a consensus rating of “Buy” from the sixteen brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and eleven have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $333.38.
A number of equities analysts have weighed in on the stock. ValuEngine cut shares of Illumina from a “buy” rating to a “hold” rating in a research report on Friday, October 25th. UBS Group upped their price objective on shares of Illumina from $350.00 to $355.00 and gave the company a “buy” rating in a research report on Tuesday, July 30th. Piper Jaffray Companies decreased their price objective on shares of Illumina from $348.00 to $341.00 and set an “overweight” rating for the company in a research report on Friday, October 25th. Guggenheim assumed coverage on shares of Illumina in a research report on Friday, October 25th. They issued a “buy” rating and a $350.00 price objective for the company. Finally, Cowen set a $320.00 price objective on shares of Illumina and gave the company a “buy” rating in a research report on Friday, October 25th.
Illumina stock traded down $1.86 during trading on Friday, reaching $293.39. 935,600 shares of the company’s stock were exchanged, compared to its average volume of 1,040,401. The company’s 50-day moving average is $302.33 and its two-hundred day moving average is $310.78. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.15 and a current ratio of 6.82. Illumina has a 52-week low of $263.30 and a 52-week high of $380.76. The firm has a market cap of $44.23 billion, a price-to-earnings ratio of 51.29, a PEG ratio of 2.22 and a beta of 1.03.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, October 24th. The life sciences company reported $1.93 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.53. Illumina had a net margin of 28.14% and a return on equity of 22.05%. The firm had revenue of $907.00 million during the quarter, compared to analysts’ expectations of $872.65 million. During the same period in the prior year, the company earned $1.52 EPS. The firm’s revenue was up 6.3% on a year-over-year basis. Analysts anticipate that Illumina will post 6.44 EPS for the current year.
In other news, SVP Charles Dadswell sold 1,220 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $279.88, for a total value of $341,453.60. Following the sale, the senior vice president now owns 5,386 shares in the company, valued at approximately $1,507,433.68. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Mostafa Ronaghi sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $285.52, for a total transaction of $2,855,200.00. Following the completion of the sale, the senior vice president now owns 86,585 shares in the company, valued at approximately $24,721,749.20. The disclosure for this sale can be found here. Over the last three months, insiders sold 32,638 shares of company stock valued at $9,580,415. 0.38% of the stock is currently owned by corporate insiders.
Several institutional investors have recently modified their holdings of the company. Cetera Advisors LLC raised its stake in shares of Illumina by 5.4% in the 3rd quarter. Cetera Advisors LLC now owns 679 shares of the life sciences company’s stock valued at $208,000 after purchasing an additional 35 shares in the last quarter. Broderick Brian C raised its stake in shares of Illumina by 0.3% in the 2nd quarter. Broderick Brian C now owns 13,240 shares of the life sciences company’s stock valued at $4,874,000 after purchasing an additional 36 shares in the last quarter. Foresight Wealth Management LLC raised its stake in Illumina by 4.2% during the second quarter. Foresight Wealth Management LLC now owns 972 shares of the life sciences company’s stock worth $358,000 after acquiring an additional 39 shares during the period. Bbva USA Bancshares Inc. raised its stake in Illumina by 2.0% during the second quarter. Bbva USA Bancshares Inc. now owns 2,020 shares of the life sciences company’s stock worth $743,000 after acquiring an additional 40 shares during the period. Finally, Zeke Capital Advisors LLC raised its stake in Illumina by 2.0% during the third quarter. Zeke Capital Advisors LLC now owns 2,044 shares of the life sciences company’s stock worth $622,000 after acquiring an additional 40 shares during the period. Institutional investors and hedge funds own 90.94% of the company’s stock.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Recommended Story: What does a hold rating mean?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.